VAG
BMRN icon

VisionPoint Advisory Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

VisionPoint Advisory Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-17
Closed -$1.4K – 304
2024
Q2 		$1.4K Buy
17
+4
+31% +$333 ﹤0.01% 697
2024
Q1 		$1.14K Buy
+13
New +$1.16K ﹤0.01% 719

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

VisionPoint Advisory Group's BMRN Position: Q3 2024 in Review

VisionPoint Advisory Group sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 17 shares — an estimated $1.4K sold.

VisionPoint Advisory Group first reported a position in BMRN in Q1 2024 and held it in 2 quarters. The position peaked at $1.4K in Q2 2024. 553 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

  • VisionPoint Advisory Group reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • VisionPoint Advisory Group sold 17 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $1.4K.
  • VisionPoint Advisory Group first reported a position in BioMarin Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • VisionPoint Advisory Group's BioMarin Pharmaceuticals position peaked at $1.4K in Q2 2024.
  • 553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on VisionPoint Advisory Group's 13F filing for Q3 2024, filed 15 Oct 2024.